Amgen and Servier last week announced that their cardiovascular collaboration has seen an advancement due to Servier deciding to exercise its option for the commercialization of omecamtiv mecarbil in Europe for chronic heart failure.
This will also include the Commonwealth of Independent States, including Russia, which were a recent addition to the collaboration.
"We are very pleased to strengthen our collaboration with Servier and for the continued advancement of the novel cardiac myosin activator omecamtiv mecarbil," Amgen EVP of Research and Development Dr. Sean E. Harper said. "We are working closely with our research collaborators and regulators on the Phase 3 outcomes study for omecamtiv mecarbil and look forward to assessing the potential of this unique therapy to benefit patients with chronic heart failure worldwide."
Under the terms of the agreement, Servier will make an option exercise payment of $10 million along with future milestone and royalty payments.
"Omecamtiv mecarbil is a very innovative approach to treating chronic heart failure, bringing new hope to patients suffering from this severe condition," Servier EVP of Research and Development Dr. Emmanuel Canet said. "We are pleased to collaborate with Amgen in the late stage of its clinical development for omecamtiv mecarbil."